CROI 2017 Comp Review

CROI 2017 Comp Review 1 

CROI2017_Comp_Button_v3


About the Program

Program Overview

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017). This program consists of four components: (1) CME Internet Symposium: CROI 2017 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (3) Rapid-Fire Review of CROI 2017: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data From CROI 2017: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HIV experts reviewing and discussing the most important studies on HIV therapy presented at CROI 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from CROI and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

All online components of the program will be accessible at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2017 and it is not sanctioned by the organizers of CROI 2017.

Back to Top  

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use data reported at CROI 2017 for counseling, testing and antiretroviral treatment to prevent HIV infection, especially in underserved communities

  • Use in a clinical setting findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at CROI 2017

  • Employ strategies based on studies and data presented at CROI 2017 for helping HIV-positive patients in medically underserved communities link to and stay in appropriate and effective HIV care

  • Discuss with patients and colleagues the studies and data on therapies for HIV/AIDS presented at CROI 2017 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS

Release Date: Feburary 24, 2017

Expiration Date: February 24, 2018

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top 

Faculty

José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain  

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Richard A. Elion, MD
Associate Professor of Clinical Medicine
George Washington University Medical Center
Washington, DC

Paul Sax, MD, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania

 


Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois

 


Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
 
Back to Top  

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

Jose Arribas, MD

  • Consulting Fees: Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: ViiV, Janssen, Abbvie, BMS,Gilead, MSD

 

Richard Elion, MD

  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Gilead, Merck, Janssen
Ian Frank, MD

 

  • Consulting Fees: Gilead
  • Contracted Research: ViiV/GSK

Graeme Moyle, MD

  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: BMS, Gilead, Merck, Tobira/Allergen, Teva, Mylan

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbvie, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Abbot, Gilead, Merck
  • Contracted Research: Gilead

Paul Sax, MD

  • Consulting Fees: Abbvie, BMS, GSK/ViiV, Gilead, Janssen, Merck
  • Contracted Research: Gilead, BMS, GSK/ViiV

Renslow Sherer, MD

  • Consulting Fees: Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouce/life partner have with commercial interests related to the content of these CME activities:

The PIM planners and managers, Trace Hutchison, PharmD,  Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Shultz, MSN, RN, CHCP have nothing to disclose.

Disclosure of Unlableled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc., and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc., and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing

 CROI17-Abstract128LB.jpg

Association Between Cardiovascular Disease
& Contemporarily Used Protease Inhibitors

 CROI17-Abstract30.jpg

HIV Incidence, Prevalence, and Undiagnosed 
Infections in Men Who Have Sex With Men

 CROI17-Abstract41.jpg

Randomized Trial of Bictegravir or Dolutegravir
with FTC/TAF for Initial HIV Therapy

 CROI17-Abstract45LB.jpg

Doravirine is Non-Inferior to Darunavir + Ritonavir
in Phase 3 Treatment-Naïve Trial at Week 48

 CROI17-Abstract39.jpg

Hepatocellular Carcinoma after SVR with
IFN-Free Regimens in HIV/HCV Co-Infection

 CROI17-Abstract137LB.jpg

Substantial Decline in Acute HCV Infections
Among Dutch HIV+MSM after DAA Roll Out

 CROI17-Abstract44LB.JPG

Phase III SWORD 1&2: Switch to DTG+RPV
Maintains Virologic Suppression Through 48 Weeks

 CROI17-PrEP

 HIV Prevention Update


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    

PIM_small

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2017 and it is not sanctioned by the organizers of CROI 2017.

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs. 

Prepare to print

Share this page:

Get link code to this page                     


Back to Top